TT 62
Alternative Names: TEI 6170Latest Information Update: 19 Oct 2000
At a glance
- Originator Teijin Pharma
- Class Antineoplastics
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Gastrointestinal cancer; Lung cancer
Most Recent Events
- 19 Oct 2000 Discontinued-II for Breast cancer in Japan (Unknown route)
- 19 Oct 2000 Discontinued-II for Gastrointestinal cancer in Japan (Unknown route)
- 19 Oct 2000 Discontinued-II for Lung cancer in Japan (Unknown route)